Search

Displaying results 2101 - 2110 of 10000 in total
  1. Drug

    Safinamide

    go.drugbank.com/drugs/DB06654
    ApprovedInvestigational

    Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  2. Drug

    Corticorelin ovine triflutate

    go.drugbank.com/drugs/DB09067
    Approved

    It is used as a diagnostic agent to evaluate the status of the pituitary-adrenal axis in the differentiation of a pituitary source from an ectopic source of excessive ACTH secretion. … If corticorelin injection results in an increase of plasma ACTH and cortisol, the patient is diagnosed with Cushing's disease.

  3. Drug

    Asciminib

    go.drugbank.com/drugs/DB12597
    ApprovedInvestigational

    Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.

  4. Drug

    Haemagglutinin-strain B (Victoria-like)

    go.drugbank.com/drugs/DB15473
    Approved

    Mixtures: Afluria Tetra Injektionssuspension in einer Fertigspritze
  5. Drug

    Etrasimod

    go.drugbank.com/drugs/DB14766
    ApprovedInvestigational

    efficacy of a 2-mg daily dose regimen of etrasimod, with a 32% and 26% remission rate observed in UC 52 and UC 12 trials respectively. … [A261826] Therefore, S1P receptor modulators like etrasimod were investigated in treating immune-mediated diseases like ulcerative colitis where a high level of inflammatory T cells is present in the gastrointestinal

  6. Drug

    Cetuximab sarotalocan

    go.drugbank.com/drugs/DB19240
    Investigational

    Cetuximab sarotalocan is under investigation in clinical trial NCT03769506 (ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

  7. Drug

    Olezarsen

    go.drugbank.com/drugs/DB18728
    ApprovedInvestigational

    Olezarsen is an antisense oligonucleotide that targets the messenger RNA (mRNA) for apolipoprotein C-III (APOC3, apoC-III),[L52033] which is a key regulator of triglyceride levels in plasma, in the liver … [A264888,A264893] Olezarsen is conjugated to a ligand containing three N-acetyl-galactosamine (GalNAc) residues to enable its delivery to hepatocytes.

    Synonyms: DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))M5RU-M5C-T-T-G-T-M5C-M5C-A-G-M5C-(2'-O-(2-METHOXYETHYL)
  8. Drug

    Erythrityl tetranitrate

    go.drugbank.com/drugs/DB01613
    ApprovedWithdrawn

    A vasodilator with general properties similar to nitroglycerin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1020)

    Categories: Vasodilators Used in Cardiac Diseases
  9. Drug

    Mipomersen

    go.drugbank.com/drugs/DB05528
    Approved

    It is marketed under the brand name Kynamro in the United States, and the FDA label includes a black box warning of hepatoxicity. … Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK … It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, L52150]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].